Product Datasheet
Sumo 2+3 Antibody
Catalog Number: 49224
Technical:tech@swbio.com
Information:info@swbio.com
Description
- Swiss-Prot No.:
- Swiss-Prot#:P55854
- Form of Antibody:
- 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.
- Immunogen:
- recombinant protein
- appl_detail:
- WB: 1:1,000
IHC: 1:50-1:200
ICC: 1:50-1:200
- other_names:
- HSMT3 antibody MGC117191 antibody OTTHUMP00000115275 antibody OTTHUMP00000115276 antibody OTTHUMP00000115277 antibody Sentrin 2 antibody Small ubiquitin like modifier 2 antibody Small ubiquitin related modifier 2 antibod
- Purification:
- ProA affinity purified
- Applications:
- WB, ICC/IF, IHC
- Background:
- The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, SUMO-2 and SUMO-3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2, and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, SUMO-2 and SUMO-3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include IkBa, MDM2, p53, PML and Ran GAP1. SUMO-2 and SUMO-3 contribute to a greater percentage of protein modification than does SUMO-1, and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates b-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease.
© Signalway Biotechnology All Rights Reserved.